Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sage Therapeutic Com (NQ: SAGE )

8.110 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 8.110
Bid (Size) 7.870 (2)
Ask (Size) 8.390 (3)
Prev. Close 8.110
Today's Range 8.110 - 8.110
52wk Range 7.700 - 28.26
Shares Outstanding 59,762,106
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Sage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire

Performance

YTD
-63.92%
-63.92%
1 Month
-24.98%
-24.98%
3 Month
-32.02%
-32.02%
6 Month
-64.29%
-64.29%
1 Year
-59.33%
-59.33%

More News

Read More
Expert Outlook: Sage Therapeutics Through The Eyes Of 14 Analysts
Via Benzinga
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Analyst Expectations For Sage Therapeutics's Future
Via Benzinga
19 Analysts Have This To Say About Sage Therapeutics
Via Benzinga
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Sage, Biogen Shelve Development Of Nervous System Disorder Drug After Data Disappoints
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Sage Therapeutics
Via Benzinga
Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails
Via Investor's Business Daily
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor
From Sage Therapeutics, Inc.
Via Business Wire
Netflix To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Sage Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
From Sage Therapeutics, Inc.
Via Business Wire
Delta Air Lines Posts Downbeat Earnings, Joins United Airlines, American Airlines And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Mama's Creations, GameStop And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Sage Therapeutics Reports Phase 2 Huntington's Data
Via Benzinga
Sage Therapeutics Announces Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntington’s Disease
From Sage Therapeutics
Via Business Wire
Sage Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
Wall Street's Top 10 Stock Calls This Week - Sunday, June 2
Via Talk Markets
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month
Via Benzinga
Sage Therapeutics to Participate in Upcoming May Investor Conferences
From Sage Therapeutics
Via Business Wire
SAGE Stock Earnings: Sage Therapeutics Misses EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Hilton Worldwide Reports Upbeat Results, Joins Hasbro, Vertiv Holdings And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.